Comparisons of Papanicolaou Utilization and Cervical Cancer Detection between Rural and Urban Women in Taiwan.
Papanicolaou test
cervical cancer
insurance claims data
rural
urban
Journal
International journal of environmental research and public health
ISSN: 1660-4601
Titre abrégé: Int J Environ Res Public Health
Pays: Switzerland
ID NLM: 101238455
Informations de publication
Date de publication:
28 12 2020
28 12 2020
Historique:
received:
03
11
2020
revised:
21
12
2020
accepted:
24
12
2020
entrez:
31
12
2020
pubmed:
1
1
2021
medline:
17
2
2021
Statut:
epublish
Résumé
Using the claims data of one million insured residents in Taiwan from 1996-2013, this study identified 12,126 women in an urban city (Taichung) and 7229 women in a rural county (Yunlin), aged 20 and above. We compared Papanicolaou (Pap) test uses and cervical cancer detection rates between urban and rural women. Results showed that the Pap screening rate was slightly higher in rural women than in urban women (86.1 vs. 81.3 percent). The cervical cancer incidence was much greater for women without Pap test than women with the test (35.8 vs. 9.00 per 1000 in rural women and 20.3 vs. 7.00 per 1000 in urban women). Nested case-control analysis showed that Pap test receivers had an adjusted odds ratio (OR) of 0.35 (95% CI = 0.25-0.51) to be diagnosed with cervical cancer as compared to those who did not receive the test. The rural women had an adjusted OR of 1.46 (95% CI = 1.03-2.06) to be diagnosed with cervical cancer as compared to urban women. In conclusion, women in rural area are at higher cancer risk than city women. Women who do not undergo Pap tests deserve timely intervention of Pap test to prevent the onset of cancer, particularly in rural women with low income.
Identifiants
pubmed: 33379209
pii: ijerph18010149
doi: 10.3390/ijerph18010149
pmc: PMC7795661
pii:
doi:
Types de publication
Comparative Study
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Références
Asian Pac J Cancer Prev. 2014;15(22):10003-8
pubmed: 25520060
N Engl J Med. 2003 Oct 16;349(16):1501-9
pubmed: 14561792
BMC Health Serv Res. 2014 Jun 02;14:240
pubmed: 24890828
Cancer Nurs. 2001 Feb;24(1):68-75
pubmed: 11219425
CA Cancer J Clin. 2019 Jan;69(1):7-34
pubmed: 30620402
J Formos Med Assoc. 2016 Dec;115(12):1076-1088
pubmed: 26786251
BMJ. 2009 Jul 28;339:b2968
pubmed: 19638651
Ann Intern Med. 2012 Jun 19;156(12):880-91, W312
pubmed: 22711081
Eur J Surg Oncol. 2015 Aug;41(8):975-85
pubmed: 25922209
Asian Pac J Cancer Prev. 2018 Mar 27;19(3):825-831
pubmed: 29582641
CA Cancer J Clin. 2018 Nov;68(6):394-424
pubmed: 30207593
Cancer. 1989 Aug 15;64(4):962-8
pubmed: 2743286
BMJ. 1999 Apr 3;318(7188):904-8
pubmed: 10102852
CA Cancer J Clin. 2015 Jan-Feb;65(1):30-54
pubmed: 25581023
Prev Med. 2011 Jul-Aug;53(1-2):82-4
pubmed: 21596056
Am J Prev Med. 2019 Sep;57(3):394-402
pubmed: 31377088
Br J Cancer. 2016 Oct 25;115(9):1140-1146
pubmed: 27632376
Medicina (Kaunas). 2019 Sep 06;55(9):
pubmed: 31500116
J Community Health. 2014 Oct;39(5):863-71
pubmed: 24863746
Cancer Res Treat. 2016 Jan;48(1):1-10
pubmed: 25943324
Public Health. 1996 Mar;110(2):123-7
pubmed: 8901257
Lancet. 2019 Jan 12;393(10167):169-182
pubmed: 30638582
Prev Med. 2013 Jun;56(6):406-9
pubmed: 23524115
Br J Cancer. 2009 Jul 7;101(1):174-7
pubmed: 19536091
BMC Public Health. 2018 Feb 14;18(1):254
pubmed: 29444640
Clin Invest Med. 2005 Oct;28(5):261-6
pubmed: 16265998
Cancer Causes Control. 2016 Jun;27(6):825-9
pubmed: 27106576
Int J Cancer. 2017 Mar 15;140(6):1293-1305
pubmed: 27925175
Res Dev Disabil. 2014 Nov 13;36C:491-497
pubmed: 25462509
Cancer Epidemiol Biomarkers Prev. 2017 Dec;26(12):1679-1694
pubmed: 28978564